Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, shared a post on X:
“Why T-DXd fails?
Paired biopsies: 49% had major HER2 drop at progression; 52% of those lost HER2 completely. Some ERBB2 ECD muts reduce binding.”
Title: Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding
Authors: Wanyi Chen, Avantika Gupta, Nicholas Mai, Sharanya Nag, Joshua S. Lau, Sukrit Singh, John D. Chodera, Bo Liu, Elisa de Stanchina, Fresia Pareja, Atif Ali Hashmi, Miriam M. Lieberman, Shanu Modi, Jacqueline Bromberg, Pedram Razavi, Joshua Z. Drago, Sarat Chandarlapaty
Read the Full article.
Other articles featuring Yüksel Ürün on OncoDaily.
